



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

#16

RECEIVED

NOV 12 1991

NOV 14 1991

Food and Drug Administration
Rockville MD 20857

OFFICE OF
COMMISSIONER

DEPT.
OF PATENTS

Re: Ganite
Docket No. 91E-0124

Charles E. Van Horn
Patent Policy and Projects Administrator
Office of the Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, DC 20231

Dear Mr. Van Horn:

This is in regard to the patent term extension application for U.S. Patent No. 4,529,593 filed by the Sloan-Kettering Institute for Cancer Research under 35 U.S.C. 156. The patent claims the human drug product Ganite, NDA 19-961.

In the May 6, 1991, issue of the Federal Register, the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. 156(d)(2)(A). The notice provided that on or before November 4, 1991, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. FDA, therefore, considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Ronald L. Wilson
Director
Health Assessment Policy Staff
Office of Health Affairs

cc: John P. White
Cooper & Dunham
30 Rockefeller Plaza
New York, NY 10112

5/14/41'